ADMET modeling approaches in drug discovery

ADMET modeling approaches 27ago19

ter, 27 ago 2019

Publicado por


Ferreira, Leonardo L.G 1 ;  Andricopulo, Adriano D. 1


In silico prediction of ADMET is an important component of pharmaceutical R&D. Last year, the FDA approved 59 new molecular entities, with small molecules comprising 64% of the therapies approved in 2018. Estimation of pharmacokinetic properties in the early phases of drug discovery has been central to guiding hit-to-lead and lead-optimization efforts. Given the outstanding complexity of the current R&D model, drug discovery players have intensely pursued molecular modeling strategies to identify patterns in ADMET data and convert them into knowledge. The field has advanced alongside the progress of chemoinformatics, which has evolved from traditional chemometrics to advanced machine learning methods.

1   Laboratory of Medicinal and Computational Chemistry, Center for Research and Innovation in Biodiversity and Drug Discovery, Sao Carlos Institute of Physics, University of  Sao Paulo, Av. Joao Dagnone 1100, 13563-120, Sao Carlos, SP, Brazil

Link to article:


Share on FacebookTweet about this on TwitterShare on LinkedInShare on Google+

0 Comentários